文献速递临床试验与 GCP流行病学与生物统计

第三项急性脑出血强化降压集束化治疗试验(INTERACT3):一项国际阶梯楔形整群随机对照试验

The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial.
PubMed 文献 · Lancet · 2023-05-25

INTERACT3是一项在九個中低收入国家和一个高收入国家开展的实用型国际多中心盲法终点阶梯楔形整群随机对照试验,评估包含早期强化降压、严格血糖控制、退热治疗和快速逆转华法林相关抗凝的目标导向集束化方案能否改善急性自发性脑出血患者结局。主要结果显示集束化组功能预后不良的似然比较低(共同比值比0.86,95%CI 0.76-0.97,p=0.015),集束化组严重不良事件少于常规治疗组(16.0% vs 20.1%,p=0.0098)。

要点

  • 集束化组功能预后不良的似然比较低(共同比值比0.86,95%CI 0.76-0.97,p=0.015)。
  • 集束化组严重不良事件发生率为16.0%,低于常规治疗组的20.1%(p=0.0098)。
  • 作者建议医院将这一集束化方案纳入临床实践,作为该类严重疾病的积极管理组成部分。

核心结论

  • 在症状出现后数小时内实施强化降压及其他生理控制管理算法的集束化方案,可改善急性脑出血患者的功能预后。
  • 作者建议医院将这一方案纳入临床实践,作为该类严重疾病的积极管理组成部分。

研究设计与样本

  • 实用型、国际、多中心、盲法终点、阶梯楔形整群随机对照试验,在九个中低收入国家(巴西、中国、印度、墨西哥、尼日利亚、巴基斯坦、秘鲁、斯里兰卡和越南)和一个高收入国家(智利)的医院开展。
  • 纳入标准为:医院无或不一致的相关疾病特异性方案、愿意对连续患者(年龄≥18岁)实施集束化方案、患者为影像学证实的自发性脑出血且在症状出现6小时内就诊、有本地倡导者并能提供所需研究数据。
  • 医院经中央随机分配采用置换区组法分为三个实施序列,按国家和研究期12个月内预计招募患者数分层;序列包含四个时期,规定医院从常规治疗对照转为集束化干预的顺序,以阶梯方式对不同患者群实施。
  • 为避免污染,干预、序列和分配时期详情对站点隐藏直至完成常规治疗对照期;分析采用改良意向治疗人群,即有可用结局数据的患者(排除研究期间退出的站点)。
  • 主要结局为6个月时盲法研究人员评估的改良Rankin量表(mRS;范围0[无症状]至6[死亡])功能恢复,采用比例序数逻辑回归分析mRS评分分布,调整聚类(医院站点)、每期聚类分组和时间(自2017年12月12日起的6个月时期)。

主要发现

  • 2017年5月27日至2021年7月8日,评估206家医院资格,144家医院同意加入并随机分配,但22家医院在开始招募患者前退出,另有一家医院因未获得监管批准被撤回且其已入组患者数据被删除。
  • 2017年12月12日至2021年12月31日,筛查10857例患者,排除3821例;改良意向治疗人群共纳入121家医院的7036例患者,集束化组3221例,常规治疗组3815例,主要结局数据可用者集束化组2892例、常规治疗组3363例。
  • 集束化组功能预后不良的似然比较低(共同比值比0.86;95%CI 0.76-0.97;p=0.015)。
  • 集束化组mRS评分有利偏移在敏感性分析中基本一致,包括额外调整国家和患者变量(0.84;0.73-0.97;p=0.017),以及采用不同多重插补方法处理缺失数据。
  • 集束化组严重不良事件少于常规治疗组(16.0% vs 20.1%;p=0.0098)。

关键数值与推荐

  • 集束化方案包括:早期强化降低收缩压(目标<140 mm Hg)、严格血糖控制(无糖尿病患者目标6.1-7.8 mmol/L,糖尿病患者目标7.8-10.0 mmol/L)、退热治疗(目标体温≤37.5°C)、华法林相关抗凝快速逆转(目标国际标准化比值<1.5)在治疗1小时内完成,适用于上述变量异常的患者。

临床怎么用

  • 作者建议医院将这一集束化方案纳入临床实践,作为该类严重疾病的积极管理组成部分。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Early control of elevated blood pressure is the most promising treatment for acute intracerebral haemorrhage. We aimed to establish whether implementing a goal-directed care bundle incorporating protocols for early intensive blood pressure lowering and management algorithms for hyperglycaemia, pyrexia, and abnormal anticoagulation, implemented in a hospital setting, could improve outcomes for patients with acute spontaneous intracerebral haemorrhage. METHODS: We performed a pragmatic, international, multicentre, blinded endpoint, stepped wedge cluster randomised controlled trial at hospitals in nine low-income and middle-income countries (Brazil, China, India, Mexico, Nigeria, Pakistan, Peru, Sri Lanka, and Viet Nam) and one high-income country (Chile). Hospitals were eligible if they had no or inconsistent relevant, disease-specific protocols, and were willing to implement the care bundle to consecutive patients (aged ≥18 years) with imaging-confirmed spontaneous intracerebral haemorrhage presenting within 6 h of the onset of symptoms, had a local champion, and could provide the required study data. Hospitals were centrally randomly allocated using permuted blocks to three sequences of implementation, stratified by country and the projected number of patients to be recruited over the 12 months of the study period. These sequences had four periods that dictated the order in which the hospitals were to switch from the control usual care procedure to the intervention implementation of the care bundle procedure to different clusters of patients in a stepped manner. To avoid contamination, details of the intervention, sequence, and allocation periods were concealed from sites until they had completed the usual care control periods. The care bundle protocol included the early intensive lowering of systolic blood pressure (target <140 mm Hg), strict glucose control (target 6·1-7·8 mmol/L in those without diabetes and 7·8-10·0 mmol/L in those with diabetes), antipyrexia treatment (target body temperature ≤37·5°C), and rapid reversal of warfarin-related anticoagulation (target international normalised ratio <1·5) within 1 h of treatment, in patients where these variables were abnormal. Analyses were performed according to a modified intention-to-treat population with available outcome data (ie, excluding sites that withdrew during the study). The primary outcome was functional recovery, measured with the modified Rankin scale (mRS; range 0 [no symptoms] to 6 [death]) at 6 months by masked research staff, analysed using proportional ordinal logistic regression to assess the distribution in scores on the mRS, with adjustments for cluster (hospital site), group assignment of cluster per period, and time (6-month periods from Dec 12, 2017). This trial is registered at Clinicaltrials.gov (NCT03209258) and the Chinese Clinical Trial Registry (ChiCTR-IOC-17011787) and is completed. FINDINGS: Between May 27, 2017, and July 8, 2021, 206 hospitals were assessed for eligibility, of which 144 hospitals in ten countries agreed to join and were randomly assigned in the trial, but 22 hospitals withdrew before starting to enrol patients and another hospital was withdrawn and their data on enrolled patients was deleted because regulatory approval was not obtained. Between Dec 12, 2017, and Dec 31, 2021, 10 857 patients were screened but 3821 were excluded. Overall, the modified intention-to-treat population included 7036 patients enrolled at 121 hospitals, with 3221 assigned to the care bundle group and 3815 to the usual care group, with primary outcome data available in 2892 patients in the care bundle group and 3363 patients in the usual care group. The likelihood of a poor functional outcome was lower in the care bundle group (common odds ratio 0·86; 95% CI 0·76-0·97; p=0·015). The favourable shift in mRS scores in the care bundle group was generally consistent across a range of sensitivity analyses that included additional adjustments for country and patient variables (0·84; 0·73-0·97; p=0·017), and with different approaches to the use of multiple imputations for missing data. Patients in the care bundle group had fewer serious adverse events than those in the usual care group (16·0% vs 20·1%; p=0·0098). INTERPRETATION: Implementation of a care bundle protocol for intensive blood pressure lowering and other management algorithms for physiological control within several hours of the onset of symptoms resulted in improved functional outcome for patients with acute intracerebral haemorrhage. Hospitals should incorporate this approach into clinical practice as part of active management for this serious condition. FUNDING: Joint Global Health Trials scheme from the Department of Health and Social Care, the Foreign, Commonwealth & Development Office, and the Medical Research Council and Wellcome Trust; West China Hospital; the National Health and Medical Research Council of Australia; Sichuan Credit Pharmaceutic and Takeda China.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Ma L, Hu X, Song L, et al. The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial. Lancet. 2023. PMID: 37245517. doi:10.1016/S0140-6736(23)00806-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。